Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2012, OCCIDENT is a venture capital organization based in Munich, Germany, and Zug, Switzerland. The firm specializes in deep-tech investments, particularly in spin-offs from scientific research, with a portfolio of nine companies. OCCIDENT aims to create tangible impact by addressing societal challenges through its investments.
OCCIDENT invests in deep-tech startups at the seed financing stage, primarily within the healthcare and biotech sectors. The firm emphasizes sustainable success potential in its investment decisions and collaborates closely with founding teams to support their growth and development.
Notable companies in OCCIDENT's portfolio include Lymphatica, which develops an implantable device for lymphedema treatment; Altavo, a startup creating non-invasive technology for artificial voices; and ReCatalyst, focused on innovative catalysts for fuel cells. Other portfolio companies include EBAMed, core sensing, Avelo, hemotune, and Tubulis.
Email your pitch deck to office@occident.group for consideration.
OCCIDENT typically leads seed rounds, providing initial funding and support to startups in its portfolio.
The firm is open to follow-on investments, particularly for companies demonstrating strong growth and sustainable success potential.
Specific details about the size of OCCIDENT's current fund are not publicly available.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.